Tags: blood cancerbortezomibcancerchemotherapydexamethasoneelotuzumabhematologyhigh-risk multiple myelomaimmunomodulator therapyimmunomodulatorsinductionlenalidomidemaintenanceMMmotor neuropathymultiple myelomamyelomaneuropathyoncologypfsphase 2 trialprogression-free survivalproteasome inhibitorrandomisedrandomised trialRVdsensory neuropathy

Want more physician-written
medical news?
Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.
Subscribe for free today!